The quest for the antibody grail

One of the most common frustrations among biologists is the difficulty to get their hands on a good antibody with a decent chance to work well in the particular assay they have in mind.

There is not one universal quality control test for antibodies and many commercial antibodies which are advertised to work well, say, in Western blot will perform poorly in immunoprecipitation and abysmally in a FACS machine. Examples abound and researchers often lament about the money spent on re-testing antibodies or repeating experiments that have failed due to poor antibody quality.

Continue reading

Geneticist seeks engineer: must like flies and worms

For geneticists working on model organisms, the job is all about linking genotype and phenotype. But nowadays, these researchers are facing a historical reversal in terms of experimental limitations. As more microarrays and other genomic tools become available—and hopefully increasingly affordable—the genotyping part of the problem, which traditionally has been most time-consuming, is not that complicated anymore. The real bottleneck is now phenotyping.

In an Editorial in Nature Methods June issue, we argue that this realization should be a call to arms for engineers.

While we think there is a crucial need to mobilize engineers to help develop assays and instrumentation for high-throughput phenotyping of model organisms, this task is not without obstacles. The Editorial starts exploring ways to make this work. What do geneticists and engineers among you think?

Idiosyncrasies of the human CMV promoter

A Correspondence in the May issue of Nature Methods points to the fact that the widely used human cytomegalovirus promoter shows dramatic differences of expression in various cell types.

The Correspondence focuses on potential problems associated with CMV in the brain in relation to a paper by Wickersham and Callaway who respond to the criticism.

Share your experience with CMV in neurons or other cell types by adding your voice to the discussion.

Social software

Don’t be mistaken, Nature Methods’ material sharing policy includes the requirement to make custom-developed software available upon publication. But there are several ways of making software available. We examine the various degrees of disclosure and the choice of formats and try to clarify our position. Let us know if we are heading in the right direction!

Open communication

The discussion topics below and some insightful comments illustrate how a commenting forum like this one can empower readers, allowing them to participate in important discussions of direct interest to their work. But readers are slow to seize this opportunity. We have taken a look at this attitude in a recent editorial.

Let us know what you think and how we can make this forum better for you.

Minimizing the risk of reporting false positives in large-scale RNAi screens

A group of investigators from various institutions have written a Commentary in which they articulate their experience about caveats of large-scale RNAi screens. These authors propose that the use of standard controls should be adopted across the community of RNAi users to minimize the risk of reporting false positives among screen results.

Far from trying to dictate rules, this Commentary seeks to open a community-wide discussion leading to a consensus of best practices that can realistically be implemented across all experimental settings. Therefore, we welcome your reactions and hope for a constructive dialog for the benefit of all. Please post your comments below.

The urgent need for such debate has been highlighted in two recent papers by Ma et al. in Nature and Kulkarni et al. in Nature Methods. These two studies demonstrate that RNAi screens in the Drosophila melanogaster system—in which long dsRNAs are used as RNAi triggers—are affected by off-target effects to a much wider extent than previously thought.

As far as the use of RNAi in mammalian systems is concerned, off-target effects have been a constant preoccupation. Nature Methods’ recent focus, RNA interference – A user’s guide, contains practical discussion of issues revolving around the use of RNAi as a research tool in mammalian systems, and includes notably a Perspective by Yi Pei and Tom Tuschl on effective siRNA design and a Perspective by Bryan Cullen on experimental design to enhance and confirm specificity. The latter is, however, focused on experimental situations in which one aims at knocking down the expression of a single, specific gene of interest in mammalian cells.

For those involved in genome-wide screens in various model organisms, like the Commentary’s authors, the recommended controls may be technically difficult to implement—hence, the need for a discussion of appropriate measures to strike the right balance between practical feasibility and accuracy of published screen results.